Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?

Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?

Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain patients, long-term results of a randomized trial found.

While the regimen did not prolong overall survival (OS) among all men with unfavorable-risk nonmetastatic cancer after a median of 10 years follow-up, it did decrease the incidence of RT-induced cancer, reported Anthony D'Amico, MD, PhD, of Dana-Farber Cancer Institute in Boston, and colleagues.

Exploratory analyses showed that men with prostate-specific antigen (PSA) levels